Cervical Cancer Screening Cascade for women living with HIV: a cohort study from Zimbabwe.


Journal

PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676

Informations de publication

Date de publication:
2022
Historique:
entrez: 2 3 2023
pubmed: 1 1 2022
medline: 1 1 2022
Statut: ppublish

Résumé

Countries with high HIV prevalence, predominantly in sub-Sahahran Africa, have the highest cervical cancer rates globally. HIV care cascades successfully facilitated the scale-up of antiretroviral therapy. A cascade approach could similarly succeed to scale-up cervical cancer screening, supporting WHO's goal to eliminate cervical cancer. We defined a Cervical Cancer Screening Cascade for women living with HIV (WLHIV), evaluating the continuum of cervical cancer screening integrated into an HIV clinic in Zimbabwe. We included WLHIV aged ≥18 years enrolled at Newlands Clinic in Harare from June 2012-2017 and followed them until June 2018. We used a cascade approach to evaluate the full continuum of secondary prevention from screening to treatment of pre-cancer and follow-up. We report percentages, median time to reach cascade stages, and cumulative incidence at two years with 95% confidence intervals (CI). We used univariable Cox proportional hazard regressions to calculate cause-specific hazard ratios with 95% CIs for factors associated with completing the cascade stages. We included 1624 WLHIV in the study. The cumulative incidence of cervical screening was 85.4% (95% CI 83.5-87.1) at two years. Among the 396 WLHIV who received screen-positive tests in the study, the cumulative incidence of treatment after a positive screening test was 79.5% (95% CI 75.1-83.2) at two years. The cumulative incidence of testing negative at re-screening after treatment was 36.1% (95% CI 31.2-40.7) at two years. Using a cascade approach to evaluate the full continuum of cervical cancer screening, we found less-than 80% of WLHIV received treatment after screen-positive tests and less-than 40% were screen-negative at follow-up. Interventions to improve linkage to treatment for screen-positive WLHIV and studies to understand the clinical significance of screen-positive tests at follow-up among WLHIV are needed. These gaps in the continuum of care must be addressed in order to prevent cervical cancer.

Identifiants

pubmed: 36860760
doi: 10.1371/journal.pgph.0000156
pmc: PMC9974171
mid: NIHMS1852975
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States

Références

Lancet Glob Health. 2021 Feb;9(2):e161-e169
pubmed: 33212031
Afr J Prim Health Care Fam Med. 2015 May 05;7(1):
pubmed: 26245601
Lancet Oncol. 2010 Feb;11(2):165-73
pubmed: 20005175
Clin Infect Dis. 2019 Oct 15;69(9):1555-1565
pubmed: 30602038
Int J Gynaecol Obstet. 2021 Jan;152(1):53-59
pubmed: 33188707
J Glob Oncol. 2018 Jul;4:1-10
pubmed: 30084698
Chin Med J (Engl). 2019 Aug 5;132(15):1773-1779
pubmed: 31335474
Int J Gynaecol Obstet. 2019 Nov;147(2):246-251
pubmed: 31482577
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):257-63
pubmed: 25886932
J Clin Epidemiol. 2020 Dec;128:83-92
pubmed: 32828836
Vaccine. 2012 Nov 20;30 Suppl 5:F24-33
pubmed: 23199964
Lancet Oncol. 2017 Dec;18(12):1665-1679
pubmed: 29126708
Pan Afr Med J. 2017 Jul 21;27:215
pubmed: 28979617
J Int AIDS Soc. 2021 Jul;24(7):e25761
pubmed: 34292649
JAMA. 2019 Oct 22;322(16):1570-1579
pubmed: 31638680
Clin Infect Dis. 2020 Dec 17;71(10):e540-e548
pubmed: 32162657
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
PLoS Med. 2021 Mar 4;18(3):e1003528
pubmed: 33661957
PLoS One. 2020 Apr 7;15(4):e0217606
pubmed: 32255796
Lancet Oncol. 2020 Jan;21(1):175-184
pubmed: 31734069
J Epidemiol Glob Health. 2020 Mar;10(1):28-35
pubmed: 32175707
N Engl J Med. 1986 Feb 20;314(8):512-4
pubmed: 3945278
Am J Obstet Gynecol. 2015 May;212(5):606.e1-8
pubmed: 25499260
Curr Opin HIV AIDS. 2016 Jan;11(1):102-8
pubmed: 26545266
Papillomavirus Res. 2019 Dec;8:100170
pubmed: 31176807
PLoS Med. 2011 May;8(5):e1001032
pubmed: 21610859
Lancet Oncol. 2019 Mar;20(3):394-407
pubmed: 30795950
PLoS One. 2019 Sep 18;14(9):e0222750
pubmed: 31532808
Int J STD AIDS. 2006 Aug;17(8):507-11
pubmed: 16925893
AIDS. 2006 Nov 28;20(18):2337-44
pubmed: 17117020
Int J Cancer. 2013 Aug 1;133(3):721-9
pubmed: 23364833
AIDS. 2017 Jan 14;31(2):233-240
pubmed: 28002084

Auteurs

Katayoun Taghavi (K)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
The Graduate School for Cellular and Biomedical Sciences of the University of Bern, Bern, Switzerland.

Ardele Mandiriri (A)

Newlands Clinic, Harare, Zimbabwe.

Tinei Shamu (T)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
The Graduate School for Health Sciences of the University of Bern, Bern, Switzerland.
Newlands Clinic, Harare, Zimbabwe.

Eliane Rohner (E)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Lukas Bütikofer (L)

CTU, University of Bern, Bern, Switzerland.

Serra Asangbeh (S)

The Graduate School for Cellular and Biomedical Sciences of the University of Bern, Bern, Switzerland.
Swiss Tropical and Public Health Institute, Basel, Switzerland.

Tsitsi Magure (T)

Newlands Clinic, Harare, Zimbabwe.

Cleophas Chimbetete (C)

Newlands Clinic, Harare, Zimbabwe.

Matthias Egger (M)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Cape Town, South Africa.

Margaret Pascoe (M)

Newlands Clinic, Harare, Zimbabwe.

Julia Bohlius (J)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.

Classifications MeSH